Cipla has launched an innovative combination ... tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person ...

Learn more› By Roderick Scott and Ryan Whitwam After a new round of testing, we’ve added the 2024 Amazon Fire HD 8 tablet as our budget pick and added Samsung’s Galaxy Tab S10+ to the ...

The shares of Cipla rocketed almost 10 per cent on the NSE (National Stock Exchange) after pharmaceutical titan's goa ...

The cool part is – thanks to his instructions, you can build one yourself! This tablet sports a FullHD touchscreen IPS display and shows some well-thought-out component mounting, using heat-set ...

Cipla managing director and global CEO Umang Vohra is optimistic about the opportunities arising for Indian pharmaceutical companies, particularly in the face of expected changes in US trade ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Shares of Cipla Ltd advanced 3 per cent in Monday's trade after the drugmaker announced a VAI status for its Goa unit, which ...

When looking for the best tablet for kids, you’ll want to consider the main ways your child will use device, as well as your budget and the tablet’s operating system. There are four main types ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

10-May-24 02-Aug-24 02-Aug-24 13 Rs.13.0000 per share(650%)Final Dividend 12-May-23 21-Jul-23 21-Jul-23 8.5 Rs.8.5000 per share(425%)Final Dividend 27-Jul-22 10-Aug-22 08-Aug-22 5 Rs.5.0000 per ...

Learn more› By Roderick Scott, Dave Gershgorn and Nick Guy Apple just announced its new $500 iPad mini tablet. We plan to test it soon, and you can read more details in our What to look forward ...

Expressing confidence in Cipla’s growth, Vohra also talks about the company’s commitment to FDA-compliant facilities in the US and its adaptability to potential disruptions, bolstered by FDA ...